In a statin‑naïve patient with known coronary artery disease, recent stent placement, and an LDL‑C of 60 mg/dL, is it appropriate to start therapy with a 10 mg dose of a statin?

No, starting with 10 mg is not appropriate in this patient

In a statin-naïve patient with established coronary artery disease and recent stent placement, you must initiate high-intensity statin therapy immediately—specifically atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily—regardless of the current LDL-C level of 60 mg/dL. 1

Why High-Intensity Statin is Mandatory

The 2024 ESC Guidelines for chronic coronary syndromes provide Class I, Level A recommendations that are unequivocal: all patients with established coronary artery disease require high-intensity statin therapy up to the highest tolerated dose 1. This is not negotiable based on baseline LDL-C levels.

The Target Goals

Your patient needs to achieve:

• LDL-C <55 mg/dL (1.4 mmol/L) AND
• ≥50% reduction from baseline LDL-C 1

Even though this patient's current LDL-C is 60 mg/dL (just above target), you cannot assume this represents their true baseline. This measurement may have been taken:

• During or shortly after the acute event (when LDL-C can be artificially lowered)
• Without knowledge of their pre-event lipid status
• In a statin-naïve state that requires the mandated 50% reduction from true baseline

The Evidence Base

High-intensity statins (atorvastatin ≥40 mg or rosuvastatin ≥20 mg) reduce LDL-C by 45-50% on average and have demonstrated:

• 22% reduction in major vascular events
• 10% reduction in all-cause mortality
• 20% reduction in coronary heart disease mortality per 1.0 mmol/L LDL-C reduction 1

Recent real-world data from the COR Lipid Registry showed that initiating dual lipid-lowering therapy (high-dose statin plus ezetimibe) at the index hospitalization achieved LDL-C targets in 69% of very high-risk patients at 4-6 weeks and 97% at 8-12 weeks 2.

The Practical Algorithm

At discharge from stent placement:

1. Start atorvastatin 40-80 mg OR rosuvastatin 20-40 mg daily 1
2. Consider adding ezetimibe 10 mg immediately if you anticipate difficulty reaching dual targets 2

At 4-6 week follow-up:

• Measure LDL-C with true baseline comparison
• If LDL-C remains ≥55 mg/dL or <50% reduction achieved: add ezetimibe 10 mg 1

At 8-12 week follow-up:

• If still not at goal on maximum statin + ezetimibe: add PCSK9 inhibitor 1

Critical Pitfalls to Avoid

Do not:

• Start with moderate-intensity statins (like atorvastatin 10 mg) in established CAD—this violates Class I recommendations 1
• Assume a single LDL-C measurement of 60 mg/dL means the patient is "close enough" to goal
• Delay high-intensity therapy based on tolerability concerns that haven't yet materialized
• Use the patient's current LDL-C as the baseline for calculating the 50% reduction target

The "strike early and strike strong" strategy is evidence-based: Starting aggressive therapy at the index event, rather than titrating up gradually, achieves guideline targets in the vast majority of patients and reduces recurrent events 2.

Special Consideration for This Patient

Given the recent stent placement, this patient is at particularly high risk for recurrent events. Data show that even among patients achieving LDL-C <70 mg/dL (1.8 mmol/L), those with polyvascular disease or other high-risk features benefit from even lower targets (<40 mg/dL) 3. Starting with inadequate therapy (10 mg) would:

• Fail to meet the mandated 50% reduction requirement
• Potentially leave the patient above the <55 mg/dL target
• Miss the critical early window for intensive risk reduction post-stenting

1, 2